Boao Lecheng emerging destination for Asian tourist high-end medical tourism

KUALA LUMPUR, Feb 5 -- Boao Super Hospital recently performed an operation of transcatheter aortic valve replacement (TAVR) in conjunction with the use of the TriGUARD3TM Cerebral Embolic Protection Device (TriGUARD3).

According to a statement, this is the first clinical application of TriGUARD3 in Asia, marking a milestone in the field of cardiovascular surgery.

Located in Boao Town, Hainan Province, Boao Lecheng International Medical Tourism Pilot Zone (the Pilot Zone) is built with high-end medical tourism service and international cutting-edge medical science and technology achievements.

It will become an emerging destination for the Asian tourist to experience high-end medical tourism.

Since last year, the Pilot Zone has set up ‘the Never End International Innovative Medicine Equipment Exhibition’, bringing down drug costs while importing synchronously latest pharmaceutical equipment worldwide.

In addition, patients can experience traditional Chinese medicine therapy in the Pilot Zone. For thousands of years, traditional Chinese medicine has been reputed for its moderate curative effects and slight side-effects. 

Last November, the first Asia Advance International Medical Centre from Singapore was opened in the Zone. Gathering international medical experts from Singapore, Korea and the UK, the Center provides diagnosis and treatment services for patients from the Chinese mainland and other neighbouring countries.

 By 2030, a world-class destination for medical tourism will be built in the Pilot Zone, providing all-round services including anti-cancer, rehabilitation, and health management.




Vivantis Technologies Elevates COVID-19 Testing Capacity In Malaysia

By Nadia Jumri

KUALA LUMPUR (Bernama) – The world has been battling COVID-19 for close to a year now, with more than 200 countries and territories affected by the pandemic.

In Malaysia, the third wave of infections led to total case numbers spiking to over 75,000. Globally, the virus has infected more than 68 million people and caused over 1.5 million fatalities.

Due to the virus’ highly virulent nature, producing COVID-19 test kits has become a top priority for certain biotechnology companies focusing on research and development (R&D) in Malaysia.



Pandangan rakyat Malaysia tentang peningkatan sasaran pemberian vaksin COVID-19 kepada 70 peratus.

UMSC: Pain Management

In Focus : UMSC Raya Open House 2018

In Focus: UMSC Consultant Speaks Erectile Dysfunction Precursor For Heart Disease Part 2

In Focus: UMSC Consultant Speaks Erectile Dysfunction Precursor For Heart Disease Part 1